ny-eso-1 iscomatrix
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2003 (NCT00518206)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cancer/testis antigen 1Immunity, active
Cancer/testis antigen 1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ny-eso-1 iscomatrix
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00199901 | Phase 2 | Sep 1, 2005 | Ludwig Institute for Cancer Research, Royal Marsden Hospital NHS Trust, University of London |
| NCT00518206 | Phase 2 | Dec 1, 2003 | Ludwig Institute for Cancer Research |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ludwig Institute for Cancer Research | Academic/Hospital | 2 | 2 | 1 | 2003 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2005 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2005 |
3 organizations
Page 1 / 1